Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65


Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination.

Sensi M, Farina C, Maccalli C, Anichini A, Berd D, Parmiani G.

J Immunother. 1998 May;21(3):198-204.


Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG.

Cancer Res. 2011 Feb 15;71(4):1253-62. doi: 10.1158/0008-5472.CAN-10-2693. Epub 2011 Jan 7.


T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.

Cole DJ, Wilson MC, Rivoltini L, Custer M, Nishimura MI.

Cancer Res. 1997 Dec 1;57(23):5320-7.


T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines.

Nishimura MI, Custer MC, Schwarz SL, Parker LL, Mixon A, Clay TM, Yannelli JR, Rosenberg SA.

J Immunother. 1998 Sep;21(5):352-62.


Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.

Willemsen R, Ronteltap C, Heuveling M, Debets R, Bolhuis R.

Gene Ther. 2005 Jan;12(2):140-6.


Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.

Sensi M, Farina C, Maccalli C, Lupetti R, Nicolini G, Anichini A, Parmiani G, Berd D.

J Clin Invest. 1997 Feb 15;99(4):710-7.


Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination.

Lee KH, Panelli MC, Kim CJ, Riker AI, Bettinotti MP, Roden MM, Fetsch P, Abati A, Rosenberg SA, Marincola FM.

J Immunol. 1998 Oct 15;161(8):4183-94.


[T cell repertoires correlate with pathogenesis of chronic idiopathic thrombocytopenic purpura].

Zhu X, Zhu P, Guo XL.

Zhonghua Yi Xue Za Zhi. 2005 Dec 14;85(47):3316-22. Chinese.


Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.

Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie PG.

Cancer Res. 2008 May 15;68(10):3931-40. doi: 10.1158/0008-5472.CAN-07-5898.


Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.

Wieckowski S, Baumgaertner P, Corthesy P, Voelter V, Romero P, Speiser DE, Rufer N.

J Immunol. 2009 Oct 15;183(8):5397-406. doi: 10.4049/jimmunol.0901460. Epub 2009 Sep 28.


A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.

Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.

Eur J Immunol. 2005 Apr;35(4):1066-75.


Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.

Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B.

Hum Immunol. 2004 Aug;65(8):794-802.


Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts.

Mackensen A, Veelken H, Lahn M, Wittnebel S, Becker D, Köhler G, Kulmburg P, Brennscheidt U, Rosenthal F, Franke B, Mertelsmann R, Lindemann A.

J Mol Med (Berl). 1997 Apr;75(4):290-6.


Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires.

Dietrich PY, Walker PR, Quiquerez AL, Perrin G, Dutoit V, Liénard D, Guillaume P, Cerottini JC, Romero P, Valmori D.

Cancer Res. 2001 Mar 1;61(5):2047-54.


The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.

François V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K, Colau D, Marchand M, Boon T, Lucas S, van der Bruggen P.

Cancer Res. 2009 May 15;69(10):4335-45. doi: 10.1158/0008-5472.CAN-08-3726. Epub 2009 May 12.


Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.

Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Ayyoub M, Valmori D.

Clin Cancer Res. 2009 Jul 1;15(13):4467-74. doi: 10.1158/1078-0432.CCR-09-0582. Epub 2009 Jun 16.


Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.

Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P.

Cancer Res. 2000 Aug 15;60(16):4499-506.

Supplemental Content

Support Center